Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8648167 | 0.87 | ROCK1 (0.47) | EGFRROCK1HTTEIF2AK2SMN1; SMN2 | |
| SCHEMBL9115422 | 0.84 | ROCK1 (0.44) | EGFRROCK1HTTKMT2AEIF2AK2 | |
| SCHEMBL7124185 | 0.82 | EGFR (0.63) | EGFRROCK1HTTALDH1A1MEN1 | |
| SCHEMBL31053046 | 0.79 | EGFR (0.60) | EGFRHTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8650527 | 0.79 | EGFR (0.67) | EGFRROCK1CSF1RPDGFRBKDR | |
| SCHEMBL8645966 | 0.79 | ROCK1 (0.47) | EGFRROCK1HTTMEN1MAPT | |
| Hydrochloric Acid SCHEMBL8649552 | 0.78 | ROCK1 (0.46) | EGFRROCK1HTTMEN1MAPT | |
| SCHEMBL7117675 | 0.77 | EGFR (0.59) | EGFRROCK1EIF2AK2PDGFRBALK | |
| SCHEMBL7128491 | 0.77 | EGFR (0.59) | EGFRROCK1EIF2AK2PDGFRBALK | |
| SCHEMBL7117678 | 0.77 | EGFR (0.59) | EGFRROCK1EIF2AK2PDGFRBALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ROCK1 177/4885HTT 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.